Vantage Technology LLC
$593.80 25 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
R-Pharm US LLC
R-Pharm US LLC reported $588.45 across General Payments, Research, and Ownership to 7 physicians and teaching hospitals across 7 transactions.
- $588.45 Below-median payer
- All-tracks total
- 7 Below-median volume
- Transactions
- 7 Below-median reach
- Recipients
- #1874
- of 1,925 companies
R-Pharm US LLC reported $588.45 across all CMS Open Payments tracks (General + Research + Ownership) to 7 physicians and teaching hospitals in Program Year 2024 - ranking #1874 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $588.45, averaging $84.06 per recipient.
R-Pharm US LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer r-pharm-us-llc R-Pharm US LLC
$588.45 · #1874/1,925 · 0.0% industry · PY2024
- TOT $588.45
- RANK #1874
- SHARE 0.0%
- TXN 7
- RCP 7
- CAT 1
- GEN $588.45
- TOP1 25.8%
- PY 2024
Volume peers
Nearest volume peer: Vantage Technology LLC ($593.80)
R-Pharm US LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for R-Pharm US LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For R-Pharm US LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 1-category general-payment breakdown below at $588.45 (100.0% of General Payments, 7 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, R-Pharm US LLC's largest category was "Food and Beverage" at $588.45 - 100.0% of General Payments.
How R-Pharm US LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $588.45 | 7 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $545.49 (92.7%) of $588.45 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for R-Pharm US LLC
The five named recipients with the highest reported General Payments from this company
- 1
Pedro Gil Solivan Ortiz
$151.60 across 1 reported transactions
- 2
Alessandro Santin
$137.37 across 1 reported transactions
- 3
Alexander Olawaiye
$113.52 across 1 reported transactions
- 4
Nuhad Ibrahim
$83.52 across 1 reported transactions
- 5
Mark Shahin
$59.48 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
R-Pharm US LLC ranks #1874 of 1,925 by total payments (bottom 3% by spend) but is notably more concentrated than that alone would suggest -- #762 of 1,838 by HHI (top 41% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Ecs Opco 1 LLC : $1.6K total payments, HHI 1973
- OrthoFundamentals, LLC : $57.3K total payments, HHI 1972
- VectivBio AG : $30.1K total payments, HHI 1971
- Trice Medical, Inc. : $369.8K total payments, HHI 1959
- Dentsply Ih Ab : $186.8K total payments, HHI 1956
- G21 Srl : $9.2K total payments, HHI 1918
- R-Pharm US LLC (this company) : $588.45 total payments, HHI 1917
- Dmg America LLC : $176.1K total payments, HHI 1902
- United Imaging Healthcare North America, Inc. : $270.2K total payments, HHI 1892
- ulrich medical USA, Inc. : $199.2K total payments, HHI 1891
- NeuroOne Medical Technologies Corporation : $44.7K total payments, HHI 1889
- Eminent Spine, LLC : $35.3K total payments, HHI 1889
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as R-Pharm US LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about R-Pharm US LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with R-Pharm US LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
LumiraDx, Inc.
$600.00 2 recipients
Compare payment profiles
Pixee Medical Inc.
$601.00 2 recipients
Compare payment profiles
Cook Biotech Incorporated
$609.12 1 recipients
Compare payment profiles
curasan, Inc.
$621.57 9 recipients
Compare payment profiles
Nurami Medical Ltd
$627.48 4 recipients
Compare payment profiles
Put this to use
R-Pharm US LLC ranks #1874 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just R-Pharm US LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.